Philadelphia-negative myeloproliferative neoplasms around the COVID-19 pandemic

A research assessment of the clinical features of patients with Philadelphia-negative MPN during the COVID-19 pandemic showed that those with primary myelofibrosis had a higher risk of mortality at 48%, than those with essential thrombocythemia at 25% and those with polycythemia vera at 19%. Rate of thrombosis differed based on COVID-19 treatment location: 1.0% for patients at home, 2.8% for patients in regular wards, and 18.4% for those in the ICU. In addition to transfer to ICU, risk factors for thrombosis included ET phenotype and neutrophil/lymphocyte ratio.